• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    115.43 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 543
    Open 115.43
    Bid (Size) 114.22 (100)
    Ask (Size) 115.79 (100)
    Prev. Close 115.43
    Today's Range 115.43 - 115.43
    52wk Range 73.31 - 125.14
    Shares Outstanding 2,531,374,696
    Dividend Yield 2.95%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
    The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
    Via MarketMinute
    Topics Artificial Intelligence Initial Public Offering Stocks
    News headline image
    Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
    Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property

    Performance

    YTD
    +8.4%
    +8.4%
    1 Month
    -5.1%
    -5.1%
    3 Month
    +15.1%
    +15.1%
    6 Month
    +42.5%
    +42.5%
    1 Year
    +21.8%
    +21.8%

    More News

    Read More
    Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals ↗
    Via Chartmill
    News headline image
    Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 ETF That Could Turn $100 Per Month Into $67,380 ↗
    Via The Motley Fool
    Topics ETFs Economy World Trade
    News headline image
    Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
    Via MarketMinute
    Topics Artificial Intelligence Economy Workforce
    News headline image
    1 Unpopular Stock That Deserves Some Love and 2 We Avoid
    Via StockStory
    News headline image
    BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
    Via MarketMinute
    News headline image
    Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
    Via Finterra
    Topics Economy Intellectual Property Lawsuit
    News headline image
    2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
    Via StockStory
    Topics Stocks
    News headline image
    1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 Undervalued Names Too Cheap to Ignore ↗
    Via MarketBeat
    News headline image
    The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    News headline image
    Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
    Via The Motley Fool
    News headline image
    Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
    Via Finterra
    Topics Intellectual Property
    News headline image
    ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
    Via MarketMinute
    Topics Earnings Economy
    News headline image
    2 High-Flying Stocks With More Upside to Buy and Hold ↗
    Via The Motley Fool
    Topics Artificial Intelligence Supply Chain
    News headline image
    IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
    Via Stocktwits
    Topics Earnings Supply Chain
    News headline image
    IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
    Via MarketMinute
    Topics Economy
    News headline image
    IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
    From Merck & Co., Inc
    Via Business Wire
    News headline image
    WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
    Via The Motley Fool
    Topics Lawsuit

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 115.43
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 03/16/26 07:00 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 292.20B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 292B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.